AIRLINK 79.90 Increased By ▲ 1.51 (1.93%)
BOP 5.26 Decreased By ▼ -0.08 (-1.5%)
CNERGY 4.35 Increased By ▲ 0.02 (0.46%)
DFML 32.80 Increased By ▲ 1.93 (6.25%)
DGKC 77.50 Decreased By ▼ -1.01 (-1.29%)
FCCL 20.34 Decreased By ▼ -0.24 (-1.17%)
FFBL 31.30 Decreased By ▼ -1.00 (-3.1%)
FFL 9.90 Decreased By ▼ -0.32 (-3.13%)
GGL 10.29 No Change ▼ 0.00 (0%)
HBL 117.88 Decreased By ▼ -0.62 (-0.52%)
HUBC 134.52 Decreased By ▼ -0.58 (-0.43%)
HUMNL 6.90 Increased By ▲ 0.03 (0.44%)
KEL 4.49 Increased By ▲ 0.32 (7.67%)
KOSM 4.72 Decreased By ▼ -0.01 (-0.21%)
MLCF 37.70 Decreased By ▼ -0.97 (-2.51%)
OGDC 133.62 Decreased By ▼ -1.23 (-0.91%)
PAEL 23.45 Increased By ▲ 0.05 (0.21%)
PIAA 26.50 Decreased By ▼ -0.14 (-0.53%)
PIBTL 7.00 Decreased By ▼ -0.02 (-0.28%)
PPL 112.80 Decreased By ▼ -0.65 (-0.57%)
PRL 27.68 Decreased By ▼ -0.05 (-0.18%)
PTC 14.67 Increased By ▲ 0.07 (0.48%)
SEARL 57.50 Increased By ▲ 1.00 (1.77%)
SNGP 66.80 Increased By ▲ 0.50 (0.75%)
SSGC 11.02 Increased By ▲ 0.08 (0.73%)
TELE 9.24 Increased By ▲ 0.09 (0.98%)
TPLP 11.62 Decreased By ▼ -0.05 (-0.43%)
TRG 72.75 Increased By ▲ 1.32 (1.85%)
UNITY 24.80 Increased By ▲ 0.29 (1.18%)
WTL 1.39 Increased By ▲ 0.06 (4.51%)
BR100 7,477 Decreased By -16.3 (-0.22%)
BR30 24,537 Decreased By -21.3 (-0.09%)
KSE100 71,779 Decreased By -273 (-0.38%)
KSE30 23,673 Decreased By -135.2 (-0.57%)
Business & Finance

Moderna plans trial of altered COVID-19 vaccine booster to address South Africa variant

  • The company said the vaccine did not see any impact from the U.K. variant - which has been shown to be more transmissible - in the tests.
  • The company said it plans to publish data from its tests against the South African and U.K. variants on the website.
Published January 25, 2021

Moderna plans trial of altered COVID-19 vaccine booster to address South Africa variant

Moderna said on Monday it plans to start clinical trials of an altered booster version of its COVID-19 vaccine aimed at the South African variant after tests showed its authorised vaccine may produce a diminished antibody response.

It will also test an additional booster shot of its authorised vaccine in trials to see if it boosts antibody reaction against the South Africa variant. The current regimen is for two shots four weeks apart.

The company said in a press release that it was being cautious and that the two-dose regimen of the vaccine was still expected to be protective against the South African and other variants detected to date.

The company said the vaccine did not see any impact from the U.K. variant - which has been shown to be more transmissible - in the tests.

The company said it plans to publish data from its tests against the South African and U.K. variants on the website bioRxiv.

Comments

Comments are closed.